Emerging Immunotherapy Approaches for Treating Prostate Cancer

被引:11
|
作者
Meng, Lingbin [1 ]
Yang, Yuanquan [1 ]
Mortazavi, Amir [1 ]
Zhang, Jingsong [2 ]
机构
[1] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, 12902 USF Magnolia Dr, Tampa, FL 33612 USA
关键词
immunotherapy; prostate cancer; immune checkpoint inhibitors; bispecific antibodies; CAR T cells; vaccines; cytokines; immunotherapeutic combinations; CAR-T-CELLS; IMMUNE-CHECKPOINT; DOUBLE-BLIND; PHASE-III; PLUS DOCETAXEL; CLINICAL-TRIAL; SIPULEUCEL-T; TUMOR MICROENVIRONMENT; DNA VACCINE; ANTIGEN;
D O I
10.3390/ijms241814347
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunotherapy has emerged as an important approach for cancer treatment, but its clinical efficacy has been limited in prostate cancer compared to other malignancies. This review summarizes key immunotherapy strategies under evaluation for prostate cancer, including immune checkpoint inhibitors, bispecific T cell-engaging antibodies, chimeric antigen receptor (CAR) T cells, therapeutic vaccines, and cytokines. For each modality, the rationale stemming from preclinical studies is discussed along with outcomes from completed clinical trials and strategies to improve clinical efficacy that are being tested in ongoing clinical trials. Imperative endeavors include biomarker discovery for patient selection, deciphering resistance mechanisms, refining cellular therapies such as CAR T cells, and early-stage intervention were reviewed. These ongoing efforts instill optimism that immunotherapy may eventually deliver significant clinical benefits and expand treatment options for patients with advanced prostate cancer.
引用
收藏
页数:26
相关论文
共 50 条
  • [31] Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
    Rahman, Md. Mominur
    Behl, Tapan
    Islam, Md. Rezaul
    Alam, Md. Noor
    Islam, Md. Mohaimenul
    Albarrati, Ali
    Albratty, Mohammed
    Meraya, Abdulkarim M.
    Bungau, Simona Gabriela
    MOLECULES, 2022, 27 (12):
  • [32] Immunotherapy for castration-resistant prostate cancer: has its time arrived?
    Slovin, Susan F.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (05) : 481 - 487
  • [33] Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy
    Wang, Ian
    Song, Liankun
    Wang, Beverly Y.
    Kalebasty, Arash Rezazadeh
    Uchio, Edward
    Zi, Xiaolin
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2022, 10 (04): : 210 - 233
  • [34] Molecular insights into the development of T cell-based immunotherapy for prostate cancer
    Dong, Baijun
    Minze, Laurie J.
    Xue, Wei
    Chen, Wenhao
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (11) : 1547 - 1557
  • [35] A Perspective of Immunotherapy for Prostate Cancer
    Silvestri, Ida
    Cattarino, Susanna
    Giantulli, Sabrina
    Nazzari, Cristina
    Collalti, Giulia
    Sciarra, Alessandro
    CANCERS, 2016, 8 (07)
  • [36] Immunotherapy for Prostate Cancer: False Promises or True Hope?
    Rekoske, Brian T.
    McNeel, Douglas G.
    CANCER, 2016, 122 (23) : 3598 - 3607
  • [37] Non-coding RNAs: Emerging roles in the characterization of immune microenvironment and immunotherapy of prostate cancer
    Yang, Feixiang
    Li, Jiawei
    Ge, Qintao
    Zhang, Yuchen
    Zhang, Meng
    Zhou, Jun
    Wang, Haitao
    Du, Juan
    Gao, Shenglin
    Liang, Chaozhao
    Meng, Jialin
    BIOCHEMICAL PHARMACOLOGY, 2023, 214
  • [38] Immunotherapy for prostate cancer: is prostate an immune responsive tumor?
    Slovin, Susan F.
    CURRENT OPINION IN UROLOGY, 2016, 26 (06) : 529 - 534
  • [39] Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks
    Comiskey, Michael C.
    Dallos, Matthew C.
    Drake, Charles G.
    CURRENT ONCOLOGY REPORTS, 2018, 20 (09)
  • [40] Immunotherapy in prostate cancer: challenges and opportunities
    Noguchi, Masanori
    Koga, Noriko
    Moriya, Fukuko
    Itoh, Kyogo
    IMMUNOTHERAPY, 2016, 8 (01) : 69 - 77